Dr. Hirsch is the Executive Director of the MIT Center for Biomedical Innovation (CBI) where she leads NEWDIGS, a 'think and do tank' that is re-engineering pharmaceutical innovation to deliver more clinical value to patients faster, in ways that work for all stakeholders. NEWDIGS' flagship project on 'Adaptive Biomedical Innovation' (ABI) helped inspire the successful EU-wide Adaptive Pathways pilot program led by the European Medicines Agency (2014-2016). Under Dr. Hirsch's leadership, NEWDIGS continues to channel multi-stakeholder thought leadership to advance other critical enablers of ABI such as 'precision financing' models for durable, and potentially curative, therapies; structured evidence planning across the product lifecycle; and disease focused 'learning ecosystems.' Her current efforts are focused largely on the NEWDIGS LEAPS Project, applying a systems approach to the planning, generation, and use of evidence, now being prototyped for Rheumatoid Arthritis, with a pilot using Massachusetts as a statewide testbed planned for launch in 2020.

Healthcare, Health, Medicine Pharmaceutical, Innovation, Healthcare Quality & Safety,